Author ORCID Identifier
Doctor of Philosophy
Sandro R.P. da Rocha
Overcoming Mechanisms of Acquired and Innate Doxorubicin Resistance Using Nanomedicine and Tumor-Associated Macrophage Immunotherapy
By Rashed M. Almuqbil, Pharm.D.
Director: Sandro R.P. da Rocha, PhD
Cancer is a leading cause of death worldwide. The available treatment for solid tumors may include surgery, radiotherapy, immunotherapy, and chemotherapy or a combination of all those regimens. Chemotherapy is widely used in the treatment of both lung cancers and breast cancer, including metastases, irrespective of type and stage. The poor rates of survival can be attributed to late diagnosis, and due to the development of acquired and innate chemoresistance. Lung tumors are intrinsically resistant to chemotherapy, thus requiring the development of predictive biomarkers to personalize chemotherapeutic agents. In breast cancer patients, continuous exposure to a single chemotherapeutic agent can lead to (acquired resistance) such as multidrug resistance.
Here, we formed a realistic in vitro model for the screening of chemotherapy, as the tumor stroma is composed of extracellular matrix, fibroblast, as well as how it is able to grow in a 3D manner. We described the formulation of a 4th generation PAMAM dendrimer and evaluated its efficacy and penetration through a 3D model of single and coculture spheroids, as a strategy to overcome doxorubicin’s resistance. Also, the efficacy of DOX in vivo as a single and in combination with the immunotherapy PLX3397 was evaluated, to modulate the tumor microenvironment in a syngeneic orthotopic Balb/c mice model by repolarizing M2 macrophages toward more M1 like macrophages, a potential strategy to enhance the innate immunity to fight cancer cells and overcome resistance and diminish distant metastasis.
© The Author
Is Part Of
VCU University Archives
Is Part Of
VCU Theses and Dissertations
Date of Submission
Available for download on Tuesday, August 11, 2026